Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $3.2 million.

  • Lifecore Biomedical, Inc. \De\'s Free Cash Flow fell 4586.04% to $3.2 million in Q2 2025 from the same period last year, while for May 2025 it was -$13.6 million, marking a year-over-year increase of 2490.35%. This contributed to the annual value of -$13.6 million for FY2025, which is 2490.35% up from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s Free Cash Flow stood at $3.2 million, which was down 4586.04% from -$4.3 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Free Cash Flow high stood at $6.0 million for Q2 2024, and its period low was -$23.3 million during Q1 2022.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Free Cash Flow averaged around -$7.9 million, with its median value being -$7.9 million (2021).
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 65863.6% in 2021, then skyrocketed by 16362.48% in 2024.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Free Cash Flow (Quarter) stood at -$10.2 million in 2021, then skyrocketed by 39.41% to -$6.2 million in 2022, then skyrocketed by 52.06% to -$3.0 million in 2023, then tumbled by 188.6% to -$8.6 million in 2024, then soared by 137.88% to $3.2 million in 2025.
  • Its Free Cash Flow stands at $3.2 million for Q2 2025, versus -$4.3 million for Q1 2025 and -$8.6 million for Q4 2024.